[1]梅灵月,黄利坚.肝硬化中医证型与临床指标的关系研究[J].医学信息,2022,35(05):52-55.[doi:10.3969/j.issn.1006-1959.2022.05.013]
　MEI Ling-yue,HUANG Li-jian.Research Progress on Correlation Between TCM Syndrome Types and Clinical Indicators of Liver Cirrhosis[J].Medical Information,2022,35(05):52-55.[doi:10.3969/j.issn.1006-1959.2022.05.013]
点击复制

肝硬化中医证型与临床指标的关系研究()

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
35卷
期数:
2022年05期
页码:
52-55
栏目:
综述
出版日期:
2022-03-01

文章信息/Info

Title:
Research Progress on Correlation Between TCM Syndrome Types and Clinical Indicators of Liver Cirrhosis
文章编号:
1006-1959（2022）05-0052-04
作者:
梅灵月; 黄利坚
（1.福建中医药大学，福建 福州 350122；2.厦门市中医院肝病科，福建 厦门 361000）
Author(s):
MEI Ling-yue; HUANG Li-jian
(1.Fujian University of Traditional Chinese Medicine,Fuzhou 350122,Fujian,China；2.Department of Hepatology,Xiamen Hospital of Traditional Chinese Medicine,Xiamen 361000,Fujian,China）
关键词:
肝硬化; Child-Pugh分级; 肝脏储备功能; 肝纤维化; 免疫因子; 中医证型
Keywords:
Liver cirrhosis; Child-Pugh classification; Liver reserve function; Liver fibrosis; Immune factors; Traditional Chinese medicine syndrome types
分类号:
R259
DOI:
10.3969/j.issn.1006-1959.2022.05.013
文献标志码:
A
摘要:
中医药治疗肝硬化有其独特优势。但目前肝硬化的中医证型尚无统一标准，一般可分为肝气郁结证、水湿内阻证、湿热蕴结证、肝肾阴虚证、脾肾阳虚证、瘀血阻络证等。研究表明，肝硬化的中医证型与Child-Pugh分级、肝脏受损程度指标、肝脏储备功能、免疫因子、肝纤维化指标、影像学状态等具有相关性。本文主要综述临床指标与肝硬化中医证型的关系，以期发现证型的客观量化条件，更好地指导中医辨证论治。
Abstract:
Traditional Chinese medicine has its unique advantages in the treatment of liver cirrhosis. However, there is no unified conclusion on the traditional Chinese medicine syndrome types of liver cirrhosis at present, which can be generally divided into liver qi stagnation syndrome, internal resistance of water and dampness syndrome, damp-heat accumulation syndrome, liver and kidney yin deficiency syndrome, spleen and kidney yang deficiency syndrome, and blood stasis blocking collaterals syndrome. Studies have shown that traditional Chinese medicine syndromes of liver cirrhosis are correlated with Child-Pugh classification, liver damage index, liver reserve function, immune factors, liver fibrosis index and imaging status. This paper mainly reviews the relationship between clinical indicators and traditional Chinese medicine syndromes of liver cirrhosis, in order to find the objective quantitative conditions of syndromes and better guide the treatment of traditional Chinese medicine syndrome differentiation.

参考文献/References:

[1]姜娜,平键,徐列明.肝星状细胞的活化机制—探寻肝纤维化新的诊断指标和治疗靶点[J].临床肝胆病杂志,2019,35(3):640-643.[2]郑旭锐,李长秦,宋健,等.姜黄素对肝纤维化模型大鼠肝组织PDGF-BB、CTGF的影响[J].中国药房,2012,23(43):4045-4047.[3]孔德松,张自力,雷娜,等.姜黄素对血小板衍生生长因子诱导活化的肝星状细胞细胞外基质的影响[J].中草药,2013,44(1):70-75.[4]孙影杰.乙肝肝硬化（代偿期）中医证型分布规律及其相关性研究[D].长春:长春中医药大学,2020.[5]赫婷.乙型肝炎肝硬化（代偿期）中医证型与客观指标之间相关性研究[D].沈阳:辽宁中医药大学,2018.[6]李兴宇.HBeAg阴性乙肝后肝硬化中医证型与客观指标的相关性[D].成都:成都中医药大学,2019.[7]于眉.肝硬化腹水辨证分型及与客观指标相关性研究[D].北京:北京中医药大学,2011.[8]赵丽红.肝炎肝硬化“肝藏血”功能异常表现与微观指标的相关性研究[D].北京:北京中医药大学,2014.[9]庞青,田峰,刘昌.血小板与肝纤维化的关系[J].实用肝脏病杂志,2011,14(4):315-317.[10]高红如.酒精性肝硬化患者中医证型与客观指标之间的相关性研究[D].沈阳:辽宁中医药大学,2016.[11]龚向京,彭中娟,戴琦.乙型肝炎肝硬化患者中医证型的临床特点分析[J].实用中西医结合临床,2014,14(11):12-14.[12]赵英红,孙和才,梁军.肝炎肝硬化中医证型与血清肝功能指标的相关性研究[J].四川中医,2011,29(11):55-56.[13]邵一婷.乙型肝炎肝硬化（代偿期）中医证候的研究[D].北京:北京中医药大学,2014.[14]曹爽,孙玉,邢辉勇,等.不同中医证型肝硬化患者淋巴细胞亚群及补体系统差异性分析[J].四川中医,2019,37(3):77-80.[15]钤培国.肝纤维化的中医证型与临床指标的相关性研究[D].太原:山西中医药大学,2017.[16]蒲永莉.肝炎后肝硬化代偿期中医证型与肝纤维化指标关系的研究[D].长沙:湖南中医药大学,2011.[17]吴颖,金玺.肝硬化代偿期肝纤维化指标与中医证型相关研究[J].实用中医内科杂志,2017,31(3):8-11.[18]武弋涵.乙肝肝硬化腹水（鼓胀）中医证型分布规律及其相关性研究[D].长春:长春中医药大学,2020.[19]王永丽.WD肝硬化腹水中医证型与检测指标相关性的前瞻性研究[D].合肥:安徽中医药大学,2015.[20]曹爽.肝硬化腹水中医证型与血常规指标相关性分析[J].当代医学,2018,24(27):133-134.[21]王虹.肝硬化门静脉高压性胃病的分类和诊断认识[J].诊断学理论与实践,2016,15(5):446-450.[22]高毅,舒劲,卢雨蓓,等.门脉高压性胃病不同中医证型分布与胃镜下黏膜病变特点分析[J].甘肃医药,2020,39(10):908-910.[23]郝尧坤,邵明义,姬丹,等.乙型肝炎肝硬化患者中医证型与门脉血流动力学参数及Child-Pugh分级相关性分析[J].中医研究,2019,32(4):12-14.[24]徐峰,王娟,王静,等.乙肝后肝硬化中医证型与IL-6、IL-28B及TNF-α表达的相关性研究[J].现代中西医结合杂志,2017,26(3):245-247,251.[25]周雨薇.肝硬化患者感染的发生与淋巴细胞亚群的相关性及中医证型特征研究[D].天津:天津中医药大学,2020.[26]吴琼,李聪聪,石雪娅,等.159例乙肝肝硬化患者T细胞亚群与中医证型及肝功能分级相关性研究[C]//中国中西医结合学会消化系统疾病专业委员会.第二十九届全国中西医结合消化系统疾病学术会议论文集,2017.[27]邵华卿,陆元仲,董静懿,等.乙肝后肝硬化患者中医证型与T细胞亚群、免疫球蛋白水平的相关性研究[J].现代免疫学,2012,32(2):156-158.[28]阮新梅.彩色多普勒超声辨别肝硬化患者中医证型的价值研究[J].新中医,2020,52(17):44-47.[29]王国鑫,倪约翰.多层螺旋CT门静脉成像在肝硬化中医证型诊断中的应用研究[J].新中医,2021,53(12):50-53.[30]刘海峰,赵小菊,张跃,等.磁共振形态学成像、DWI、DKI在乙肝后肝硬化中医证候分型中的价值[J].中国中医基础医学杂志,2019,25(5):617-620.

相似文献/References:

[1]崔 洁.凝血酶原时间与血小板检验方式对诊断肝硬化疾病的临床价值研究[J].医学信息,2018,31(04):150.[doi:10.3969/j.issn.1006-1959.2018.04.055]
　CUI Jie.Study on the Clinical Value of Prothrombin Time and Platelet Examination in the Diagnosis of Liver Cirrhosis[J].Medical Information,2018,31(05):150.[doi:10.3969/j.issn.1006-1959.2018.04.055]
[2]祁兴顺,周新苗,许向波,等.肝硬化患者应用特利加压素治疗期间发生 低钠血症的现状研究[J].医学信息,2018,31(09):1.[doi:10.3969/j.issn.1006-1959.2018.09.001]
[3]张铁彪,刘建华,马长顺.肺癌肿瘤标记物结合胸部CT检查肺结节的定性分析[J].医学信息,2022,35(10):171.[doi:10.3969/j.issn.1006-1959.2022.10.044]
　ZHANG Tie-biao,LIU Jian-hua,MA Chang-shun.Qualitative Analysis of Lung Cancer Tumor Markers Combined with Chest CT Examination of Pulmonary Nodules[J].Medical Information,2022,35(05):171.[doi:10.3969/j.issn.1006-1959.2022.10.044]
[4]赵华莹,李运泽,韦天灵,等.肝硬化合并门静脉血栓形成的危险因素分析[J].医学信息,2019,32(03):86.[doi:10.3969/j.issn.1006-1959.2019.03.026]
　ZHAO Hua-ying,LI Yun-ze,WEI Tian-ling,et al.Analysis of Risk Factors for Cirrhotic Patients with Portal Vein Thrombosis[J].Medical Information,2019,32(05):86.[doi:10.3969/j.issn.1006-1959.2019.03.026]
[5]王晓刚.利拉鲁肽联合胰岛素泵对2 型糖尿病合并肝硬化患者血糖代谢及肝纤维化的影响[J].医学信息,2018,31(20):136.[doi:10.3969/j.issn.1006-1959.2018.20.041]
　WANG Xiao-gang.Effects of Liraglutide Combined with Insulin Pump on Blood Glucose Metabolism and Liver Fibrosis in Patients with Type 2 Diabetes Mellitus Complicated with Cirrhosis[J].Medical Information,2018,31(05):136.[doi:10.3969/j.issn.1006-1959.2018.20.041]
[6]张宏程.生长抑素联合泮托拉唑治疗肝硬化合并上消化道出血的疗效观察[J].医学信息,2019,32(03):153.[doi:10.3969/j.issn.1006-1959.2019.03.050]
　ZHANG Hong-cheng.Therapeutic Effect of Somatostatin Combined with Pantoprazole on Hepatic Cirrhosis Complicated with Upper Gastrointestinal Hemorrhage[J].Medical Information,2019,32(05):153.[doi:10.3969/j.issn.1006-1959.2019.03.050]
[7]姜海燕.双歧杆菌四联活菌治疗对肝硬化患者肝功能、细胞因子及肠道菌群的影响[J].医学信息,2022,35(12):156.[doi:10.3969/j.issn.1006-1959.2022.12.038]
　JIANG Hai-yan.Effect of Quadruple Viable Bifidobacterium Treatment on Liver Function, Cytokines and Intestinal Flora in Patients with Liver Cirrhosis[J].Medical Information,2022,35(05):156.[doi:10.3969/j.issn.1006-1959.2022.12.038]
[8]张许林,余泽波.肝硬化上消化道出血的输血治疗进展[J].医学信息,2019,32(08):85.[doi:10.3969/j.issn.1006-1959.2019.08.025]
　ZHANG Xu-lin,YU Ze-bo.Progress in Transfusion Therapy for Upper Gastrointestinal Hemorrhage[J].Medical Information,2019,32(05):85.[doi:10.3969/j.issn.1006-1959.2019.08.025]
[9]陈 杰.左旋肉碱治疗肝硬化并显性肝性脑病的效果观察[J].医学信息,2019,32(14):153.[doi:10.3969/j.issn.1006-1959.2019.14.051]
　CHEN Jie.Effect of L-carnitine on Liver Cirrhosis and Dominant Hepatic Encephalopathy[J].Medical Information,2019,32(05):153.[doi:10.3969/j.issn.1006-1959.2019.14.051]
[10]宋少娟,苏国华.血清总胆汁酸、胆碱酯酶和前白蛋白检测在肝病诊断中应用探析[J].医学信息,2021,34(23):9.[doi:10.3969/j.issn.1006-1959.2021.23.002]
　SONG Shao-juan,SU Guo-hua.Application of Serum Total Bile Acid, Cholinesterase and Prealbumin Detection in the Diagnosis of Liver Disease[J].Medical Information,2021,34(05):9.[doi:10.3969/j.issn.1006-1959.2021.23.002]
[11]桂志兵,汪文生.红细胞分布宽度与血小板计数比值在乙型肝炎肝硬化患者病情评估中的作用[J].医学信息,2018,31(20):65.[doi:10.3969/j.issn.1006-1959.2018.20.019]
　GUI Zhi-bing,WANG Wen-sheng.The Role of Red Blood Cell Distribution Width and Platelet Ratio in the Evaluation of Patients with Hepatitis B Cirrhosis[J].Medical Information,2018,31(05):65.[doi:10.3969/j.issn.1006-1959.2018.20.019]
[12]刘立楠.肝硬化患者上消化道出血危险因素与预后影响因素分析[J].医学信息,2021,34(14):3.[doi:10.3969/j.issn.1006-1959.2021.14.002]
　LIU Li-nan.Analysis of Risk Factors and Prognostic Factors of Upper Gastrointestinal Bleeding in Patients with Liver Cirrhosis[J].Medical Information,2021,34(05):3.[doi:10.3969/j.issn.1006-1959.2021.14.002]

更新日期/Last Update: 1900-01-01